Response to "Role of regulators in safe prescribing of opioids"
- PMID: 28923800
- PMCID: PMC5602503
- DOI: 10.1503/cmaj.733208
Response to "Role of regulators in safe prescribing of opioids"
Conflict of interest statement
Competing interests: Owen Williamson reports nonfinancial support from Health Canada, and personal fees and nonfinancial support from Purdue Pharma (Canada), Mundipharma International Ltd. and INVIVO Communications Ltd., outside the submitted work. Andrea Furlan is acknowledged in the 2017 “Guideline for Opioid Therapy and Chronic Noncancer Pain.” She participated in the first meeting of the clinical experts in January 2016 but was not involved in the remaining development of the guideline.
Comment on
-
New Canadian guidance on opioid use for chronic pain: necessary but not sufficient.CMAJ. 2017 May 8;189(18):E650-E651. doi: 10.1503/cmaj.170431. CMAJ. 2017. PMID: 28483843 Free PMC article. No abstract available.
-
Role of regulators in safe prescribing of opioids.CMAJ. 2017 Sep 18;189(37):E1195. doi: 10.1503/cmaj.733125. CMAJ. 2017. PMID: 28923799 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources